

Quality System: Updates from FDARA and 21st Century Cures Act

**FDA Small Business
Regulatory Education for Industry (REdI)
Boston, MA
May 30, 2019**

Vidya Gopal
Consumer Safety Officer
Division of Industry and Consumer Education
Office of Communication and Education
Center for Devices and Radiological Health
U.S. Food and Drug Administration



Learning Objectives

Summarize the changes to postmarket requirements from:

- FDA Reauthorization Act (FDARA)
- 21st Century Cures Act
- Other Postmarket updates

FDARA

FDA Reauthorization Act

- Abbreviated as [FDARA](#)
- Enacted August 18, 2017
- Purpose
 - Reauthorize various FDA user fee programs- MDUFA, PDUFA, GDUFA, and BsUFA
 - Make policy and program changes
- [CDRH Learn Module on MDUFA](#)

FDARA 701: Authorizes...

Section 701 : Inspections

- Risk based inspection scheduling for device establishments
- Replaced previous biennial inspection requirement

FDARA 702: Authorizes...

Section 702: Improvements to Inspections

- Inspection announcement, timing, and communication
- FDA to provide nonbinding feedback within 45 calendar days of request
- Draft guidance issued by February 18, 2019 and finalize

FDARA: FDA Actions...

Section 702: Inspections

- FDA issued Draft Guidance for [Nonbinding feedback after certain FDA Inspections of device establishments](#)
- Issued on February 19, 2019

FDARA 703: Authorizes...

Section 703: Third Party Inspections

- Reauthorizes Third Party Inspections (Accredited Persons Program)
- Scheduled to expire October 01, 2017, extended to October 01, 2022

FDARA 704: Authorizes...

Section 704: Export certificates

- Provide reason to deny an export certificate
- When establishment agrees to a plan to correct 483 violations, FDA will not deny an export certificate
- Create a process for FDA to review denials
- Draft guidance issued by August 18, 2018 and finalize

FDARA 704: FDA Actions...

Section 704: Export certificates

- FDA issued a Draft Guidance “[Process to request a review of the FDA’s decision not to issue certain export certificates for devices](#)”
- Issued on August 17, 2018

FDARA 705: Authorizes...

Section 705: Medical Device Single Audit Program (MDSAP)

- Authorizes FDA to recognize auditing organizations
- Facilitates harmonization of medical device inspections

FDARA 705: Actions....

Section 705: Medical Device Single Audit Program (MDSAP)

- MDSAP is no longer a pilot and is an active program

FDARA 707: Authorizes...

Section 707: Accessories

- Allows accessory classification to be distinct from classification of parent device

Examples

Parent device




Photo credit – drugs.com

Accessory



Photo credit – ebay and Medtronic

FDARA 707: Authorizes...

Section 707: Accessories

- Classification is based on risk
- Requires FDA to respond to accessory classification requests within 85 calendar days
- Classify suitable accessories into Class I of the proposed list published on August 17, 2018

FDARA 707: FDA Actions...

Section 707 – Accessories

- FDA issued a final classification action [Medical devices classification of accessories distinct from other devices finalized list of accessories suitable for Class I](#)
- Issued on April 12, 2018

FDARA 707: FDA Actions...

Section 707 – Accessories

- FDA issued a guidance [Medical Device Accessories – Describing Accessories and Classification Pathway for New Accessory Types](#)
- Issued on December 20 , 2017

FDARA 707: FDA Actions...

- If accessory classification is distinct from another device prior to December 31, 2016:
 - Classification stands, unless reclassified
- If accessory is included in pending or future premarket submission:
 - Sponsor may include a request for the classification
 - FDA must include a grant or denial of the request for classification of the accessory

FDARA 707: FDA Actions...

- If accessory was included as part of a premarket submission:
 - Sponsor may include a request for the classification
 - FDA must respond by reclassifying or denying the request within 85 days.

FDARA 708: Authorizes...

Section 708: Postmarket Surveillance Pilots

- Designed to generate reliable and timely safety and surveillance data
- Inform development of methods, systems, criteria, and programs for devices
- May be designed and conducted in coordination with a comprehensive system for evaluating device technology

FDARA 708: Authorizes...

Section 708: Postmarket Surveillance Pilots

- Use electronic health data
- Prioritize devices and device types based on:
 1. The collection of real world evidence (RWE) is likely to advance public health
 2. Devices that are widely used
 3. Device failure with significant health consequences



FDARA 708: FDA Authorizes...

Section 708 - Postmarket Surveillance Pilots

- Report to Congress by February 18, 2019 and annually thereafter
- Independent review by January 31, 2021

FDARA 708: FDA Actions...

Section 708: Postmarket Surveillance Pilots

- Awarded funding to Medical Device Innovation Consortium (**MDIC**)
- To establish the National Evaluation System for Health Technology Coordinating Center (**NESTcc**)

www.meddeviceonline.com/doc/nestcc-at-two-progress-and-next-steps-for-real-world-evidence-for-medical-devices-0001

FDARA 708 Pilot Examples

First round of NESTcc Test Cases

Total Product Life Cycle (TPLC) Alignment	Project Title	Regulatory Pathway	Technology of Interest	Disease Area
Pre-market Submission	Comparative Effectiveness of Alternative Approaches for Wound Closure	510(k)	Wound Closure	Dermatology
Label Expansion	Testing the Use of Real-World Data from Three Unique Sources to Expand Indications	PMA	Endovascular Therapies	Vascular
Label Expansion	The Feasibility of Using Real-World Data in the Evaluation of Cardiac Ablation Catheters	PMA	Ablation Catheters	Cardiology

FDARA 710: Authorizes...

Section 710: Third Party Servicers

By May 15, 2018, post a report that includes:

- Information from 2016 FR notice and public workshop
- Authorities FDA has to regulate servicers and actions FDA can take
- Information about regulation of servicing by states, the Joint Commission, and other regulatory authorities

FDARA 710: FDA Actions...

Section 710: Third Party Servicers

FDA posted the [report](#)

- Issued May 2018
- This report was informed by feedback from all stakeholder groups

FDARA 710: FDA Actions...

Section 710: Third Party Servicers

Intended FDA actions:

- Promote adoption of Quality Management principles
- Clarify difference between Servicing and Remanufacturing
- Strengthen Cybersecurity practices associated with servicing
- Foster evidence development

FDARA 902: Authorizes...

Section 902: Annual report of inspections

- Requires FDA to post information related to inspections for the approval of medical devices.
- Post by March 1 of each year

FDARA 902: FDA Actions...

Section 902: Annual report of inspections

- The FDA has posted the [FDARA reports](#)

FDARA 903: Authorizes...

Section 903: Real time quarterly reports

- Requires FDA to provide Real Time reporting related to the process for the review of FDA regulated products.

FDARA 902: FDA Actions...

Section 903: Real time quarterly reports

- The FDA has posted the [FDARA reports](#)

21st Century Cures Act

21st Century Cures Act

- Abbreviated as **Cures**
- Enacted December 13, 2016
- Implemented in 2017
- Amended the Federal Food, Drug, and Cosmetic Act (FD&C Act)

21st Century Cures Act

- Designed to expedite medical device development
- Bring new innovations to the market sooner
- Incorporate patient perspective into decision making process

21st Century Cures Act

- Section 510(o) revised definition of device in Section 201(h) of FD&C Act
- Does not include certain software that:
 - Supports administrative functions
 - Encourages healthy lifestyle
 - Serves Electronic health records (EHR)
 - Displays and sorts records
 - Provides limited clinical decision support

21st Century Cures Act

- FDA published a draft guidance [Changes to Existing Medical Software Policies resulting from 21st century cures act](#)
- Issued on December 08, 2017
- The concepts will be made throughout:
 - General wellness
 - Mobile medical application
 - Off the Shelf Software
 - Medical Device Data Systems (MDDS)

Other Postmarket updates

Recent Postmarket Updates

- FDA issued a guidance document [Manufacturing site change supplements: content and submission](#)
- Issued on December 17, 2018

To Subscribe

FDA

Subscribe to CDRH Mailing Lists

[f Share](#) [t Tweet](#) [in LinkedIn](#) [✉ Email](#) [🖨 Print](#)

About the Center for Devices
and Radiological Health

[CDRH Mission, Vision and
Shared Values](#)

[Reorganization of The Center
for Devices and Radiological
Health](#)

[About the Center for Devices](#)

Sign up to receive email updates on these CDRH topics - you may unsubscribe at any time. You can also edit your [Email Subscription Settings here](#).

Content current as of:
05/17/2018

CDRH New

The previous business-day's new additions to the CDRH website.

Email Address

[Subscribe](#)

CDRH Industry

Resources

- [Email subscriptions](#)
- [FDARA](#)
- [Nonbinding feedback after certain FDA Inspections of device establishments](#)
- [Process to request a review of the FDA's decision not to issue certain export certificates for devices](#)
- [Medical devices classification of accessories distinct from other devices finalized list of accessories suitable for Class I](#)
- [Medical Device Accessories – Describing Accessories and Classification Pathway for New Accessory Types](#)
- [www.meddeviceonline.com/doc/nestcc-at-two-progress-and-next-steps-for-real-world-evidence-for-medical-devices-0001](#)

Resources

- [Third Party Servicing Report](#)
- [FDARA reports](#)
- [21st Century Cures Act](#)
- [Changes to Existing Medical Software Policies resulting from 21st century cures act](#)
- [Manufacturing site change Supplements: content and submission](#)

Summary

- The FDA Reauthorization Act incorporated a number of changes that impacted devices in the postmarket setting.
- The 21st Century Cures Act is intended to help advance getting innovative products to market.

Questions?

Your Call to Action

- Keep current with regulatory changes being made by the U.S. Food and Drug Administration (FDA)
- Subscribe to the FDA email list to receive important information coming directly from FDA (as mentioned in slide 35)

